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Abstract
Background: MART-1, Melan-A, and Tyrosinase have shown encouraging results for evaluation
of melanoma micrometastases in sentinel lymph nodes, as compared to conventionally used S-100
protein and HMB-45. To achieve higher sensitivity, some studies recommend evaluation of three
sections, each at intervals of 200 µ. This would mean, routine staining of three adjacent sections in
each of the three clusters at intervals of 200 µ, requiring nine slides resulting in added expense. If
a cocktail of these antibodies could be used, only one section would be required instead of three
generating significant cost savings.
Methods: We prepared a combination of monoclonal antibodies to these three immunomarkers
in optimized dilutions (MART-1, clone M2-7C10, dilution 1:500; Melan-A, clone A103, dilution
1:100; and Tyrosinase, clone T311, dilution 1:50) and designated it as 'MCW melanoma cocktail'.
Formalin-fixed paraffin-embedded tissue sections of sentinel lymph nodes from patients with
cutaneous melanoma, without macro-metastases were evaluated with this cocktail.
Results: Melanoma micrometastases were easily detectable with the cocktail in 41 out of 188
slices (8/24 cases). The diagnostic accuracy amongst five pathologists did not show statistically
significant difference. Out of 188 slices, 78 had adjacent sections immunostained individually with
MART-1 and Melan-A during our previous study. Of these 78 slices, 21 were positive for melanoma
micrometastases with MART-1 and Melan-A individually. However, the adjacent section of these
slices immunostained with the cocktail detected metastases in four additional slices. Thus, MART-
1 and Melan-A could not detect melanoma micrometastases individually in 16% (4/25) of slices
positive with the cocktail. Benign capsular nevi were immunoreactive for the cocktail in 4.8% (9/
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188) slices. All 81 slices of negative test controls (sentinel lymph nodes of mammary carcinoma)
were interpreted correctly as negative for melanoma micrometastases.
Conclusions: The melanoma cocktail facilitated easy interpretation of melanoma micrometastases
in sentinel lymph nodes with high interobserver agreement. There was improvement in detection
rate with the cocktail as compared to MART-1 and Melan-A individually. Furthermore, this
approach facilitates cost savings.
Background
Lymphadenectomies with routine histopathologic evalu-
ation have been performed for staging and regional con-
trol of primary cutaneous melanoma, even in cases
without clinical evidence of metastasis. Because of signif-
icant morbidity associated with the procedure, regional
lymphadenectomy has been generally recommended only
for patients with evidence of regional lymph node in-
volvement [1]. To assess the involvement of regional
lymph nodes, the biopsies of sentinel lymph nodes are in-
valuable for detecting occult metastases without the sig-
nificant morbidity associated with lymphadenectomy [2–
8]. Previous studies have reported that the status of senti-
nel lymph node is an accurate reflection of the regional
lymph node status as a whole and that treatment deci-
sions can be made based on the results of sentinel lymph
nodes alone [9–11].
Previously, we had demonstrated higher diagnostic accu-
racy in detecting and diagnosing melanoma micrometas-
tases in sentinel lymph node using monoclonal
antibodies to MART-1 (clone M2-7C10) and Melan-A
(clone A103) in comparison to the traditionally used im-
munohistochemical markers, S-100 protein (S-100) and
HMB-45 [6]. The cytoplasmic staining with these immu-
nomarkers does not obscure the nuclear details and facil-
itates accurate interpretation of tumor cells, macrophages,
and nevus cells in contrast to S-100 [6,12]. A monoclonal
antibody to a third melanoma immunomarker, Tyrosi-
nase (clone T311), showed an immunostaining pattern
similar to MART-1 and Melan-A [13].
In the present study, we evaluated the combination of
monoclonal antibodies; MART-1, Melan-A, and Tyrosi-
nase in optimized titers (Table 1) for evaluation of senti-
nel lymph nodes of cutaneous melanoma. We designated
this combination after our institution as 'MCW melano-
ma cocktail' [6,14]. Hypothetically, due to the immunore-
activity of the cocktail towards three epitopes of two
antigens in the same tissue section, combined use of these
immunomarkers should increase the sensitivity while still
maintaining their individual high specificity. The possi-
bility of using a cocktail of these monoclonal antibodies
for the evaluation of melanoma sentinel lymph node
would require only one section as compared to three ad-
jacent sections for each of the immunomarker, with re-
sultant cost savings of approximately two thirds.
The aim of this study was to evaluate the accuracy of de-
tecting and interpreting micrometastases in the sentinel
lymph nodes of patients with cutaneous melanoma utiliz-
ing this cocktail in a single section instead of three adja-
cent sections needing each of the three immunomarkers
in the cocktail. We also compared the cocktail against
MART-1 and Melan-A individually.
Methods
Sentinel lymph node specimens were grossed as described
previously [6]. Formalin-fixed paraffin-embedded tissue
sections of 269 slices were evaluated with the cocktail
(Figure 1). In some cases more than one lymph nodes
were submitted as sentinel lymph nodes. The fresh, un-
fixed sentinel lymph nodes were transected into slices no
thicker than 3 mm across the long axis from one pole to
the other. They were fixed flat in formalin after wrapping
them in tissue paper to avoid curling and were processed
for paraffin embedding.
The test group included 188 slices of 88 sentinel lymph
nodes (3 to 6 slices per lymph node) from 24 cases (1 to
4 lymph nodes per case) of AJCC stage I and II cutaneous
melanoma lacking metastases which were easily detecta-
ble in sections stained with hematoxylin and eosin. These
lymph nodes were from various regions other than the ax-
illary areas. A negative test control group was studied to
verify the specificity of the cocktail. It consisted of 81 slic-
es of 30 sentinel lymph nodes (3 to 5 slices per lymph
node) from the axillary area in 30 cases of mammary car-
cinoma, of which 40 slices were positive for mammary
carcinoma metastases (Figure 1).
All the sections in the test group and negative control
group were immunostained with the cocktail (the details
of antibodies in the cocktail are shown in Table 1). As a
standardization process to confirm positive immunoreac-
tivity, 35 melanomas (including one spindle cell melano-
ma and one clear cell melanoma) were evaluated. All 35
melanomas were immunoreactive with the cocktail. Anti-
bodies from a few additional sources, other than those
mentioned in Table 1, were also evaluated. However, only
the antibodies from the sources mentioned in Table 1BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/15
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with heat antigen retrieval protocol achieved optimum re-
sults without significant background staining.
The sections were pretreated for antigen retrieval using
'Dako pH 6.0 target retrieval solution'® (Dako Corpora-
tion, Carpinteria, CA) at 95–100°C for 35 minutes and
cooled at room temperature for 20 minutes. The target re-
Figure 1
Algorithm showing the processing of sections of sentinel lymph nodes (HE, hematoxylin and eosin). *Immediately adjacent level 
to these sections during previous study [Ref# [27]] were immunostained with the cocktail during this study.
Table 1: Details of the monoclonal antibodies in the 'MCW Melanoma Cocktail'.
Marker Clone Source *Final Dilution in the cocktail
MART-1 M2-7C10 Signet Laboratories, Inc. Dedham, MA 1:500
Melan-A A103 Dako Corporation, Carpinteria, CA 1:100
Tyrosinase T311 Novocastra Laboratories Ltd Newcastle upon Tyne, UK 1:50
* Optimum dilution for each antibody was standardized individually for that batch of antibodies with the sections of known melanoma positive con-
trol. The standardized dilution was achieved as final titer in the cocktail by adding 20 µl MART-1, 100 µl Melan-A, and 200 µl Tyrosinase to 9.68 ml 
of DAKO Antibody diluent (Dako Corporation, Carpinteria, CA).
*
*
*
Test group
(88 sentinel lymph 
nodes of
cutaneous 
melanoma)
Negative control 
group
(30 sentinel lymph 
nodes of
mammary 
carcinoma)
The cocktail
(All 188 sections)
HE stain
(All 188 sections)
Melan-A
(78 sections)
MART-1
(78 sections)
The cocktail
(All 81 sections)
HE stain
(All 81 sections)
188 slices
88 sentinel lymph nodes from 24 cases
(without macro-metastases)
Cases from previous study, 
Shidham et al, Am J Surg Pathol 
25(8):1039-1046,2001
40 slices
15 sentinel lymph nodes s from 15 cases
(with macro-metastases)
41 slices
15 sentinel lymph nodes from 15 cases
(without metastases)BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/15
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trieval solution must be at a temperature of 95–100°C
from the start. The duration of this heat antigen retrieval
step was crucial for avoiding non-specific background
staining. It was optimal for all the three antibodies in the
cocktail.
Three-micron thick serial sections of paraffin-embedded
tissue blocks were numbered consecutively from 1 to 3.
Section #1 was stained with hematoxylin and eosin. Sec-
tion #2 was immunostained with 'melanoma cocktail' us-
ing Diaminobenzidine Hydrochloride (DAB) as a
chromogen. Section #3 was used as a negative control
without primary antibody. A positive control consisting of
a formalin-fixed paraffin-embedded tissue section of
melanoma demonstrating reactivity for the cocktail was
processed with each batch of slides. Two adjacent sections
were immunostained with MART-1 and Melan-A respec-
tively during our previous study on 78 out of 188 slices
(from 14 cases) [6]. The immediately adjacent unstained
sections during the previous study were used. They were
immunostained with the cocktail in this study.
Five pathologists interpreted all immunostained slides in-
dependently to determine the presence of melanoma mi-
crometastases. Whenever indicated, respective adjacent
hematoxylin and eosin stained sections and negative con-
trol sections were also used to facilitate the final
interpretation.
Statistical evaluation for degree of interobserver agree-
ment was based on the Receiver Operating Characteristic
(ROC) curve, which takes into consideration the non-bi-
nary spectrum of surgical pathology interpretation [6,15–
19]. For the generation of the ROC curve and to calculate
the areas under the ROC curves (Az values), the spectrum
of the interpretation was spread into five points with neg-
ative and positive at each end [6].
A consensus binary negative or positive diagnosis was
reached by all five pathologists in tandem under a multi-
head microscope. This was used as the final diagnosis for
statistical analysis. Az values by different observers for 188
sections were compared using non-parametric methods
based on the Mann-Whitney statistics [20]. SAS statistical
software (The SAS institute, Cary, NC) was implemented
for this statistical analysis (Table 2).
Results
Of the 188 sections immunostained with 'melanoma
cocktail', 41 sections (8/24 cases) were positive for
melanoma micrometastases (Figure 2A &2B). Az values
for the cocktail by all five pathologists were high and
ranged from 0.8525 to 1.000 (maximum possible Az val-
ue is 1.000) without statistically significant differences (p
.0743) (Table 2).
In general, the micrometastases were subtle and difficult
to detect in the hematoxylin and eosin stained sections
alone. Depending on the observer, micrometastases of
melanoma in 41 slices were detectable in only 30–45% of
hematoxylin and eosin sections. However, with closer me-
thodical scrutiny, these micrometastases were seen retro-
spectively in all 41 adjacent sections stained with
hematoxylin and eosin. All 81 sections from sentinel
lymph nodes of mammary carcinoma in the negative test
control group (Figure 1) were interpreted unequivocally
as negative for melanoma micrometastases by each of the
five pathologists (Figure 2C).
Out of 188 slices, a pool of sections immunostained indi-
vidually with MART-1 and Melan-A during our previous
study (Figure 1) were compared with the cocktail.
Melanoma micrometastases were detected in 21 of 78 slic-
es immunostained with MART-1 and Melan-A individual-
ly. However, 25 slices demonstrated micrometastases with
the cocktail. These four slices (from 2 lymph nodes of 2
cases), negative for micrometastases with MART-1 and
Melan-A, showed melanoma micrometastases predomi-
nantly as single cells. These micrometastases were detect-
able retrospectively in adjacent sections stained with
hematoxylin and eosin in all four slices. Thus, MART-1
and Melan-A individually could not detect micrometas-
tases in 16% (4/25) of the slices. No sections which were
negative for micrometastases with the cocktail demon-
Table 2: Evaluation of interobserver reproducibility in 188 sections.
Marker Observer Az p value*
A 0.8525
MCW B 0.9268 .0743
melanoma C 0.9205
cocktail D 0.9487
E 1.0000
Az, Area under ROC curves. * Mann-Whitney statisticsBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/15
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strated micrometastases with MART-1 and Melan-A
individually.
The 'melanoma cocktail' did not show background stain-
ing of non-melanocytic cells in the sentinel lymph nodes
(Figure 2 and 3) and demonstrated immunostaining pat-
tern identical to MART-1 and Melan-A reported previously
[6]. 5% (9/188) slices from 21% (5/24) of the cases
showed groups of cohesive spindle cells which were im-
munoreactive for the cocktail in the capsule of sentinel
lymph nodes. The bland nuclear morphology of these
spindle cells was consistent with benign capsular melano-
cytic nevi (Figure 3). None of the 81 sections of sentinel
lymph nodes from 30 cases of mammary carcinoma dem-
onstrated benign capsular melanocytic nevi.
Discussion
At present histomorphologic examination with immuno-
histochemistry remains the most reliable and practical
means of detecting melanoma micrometastases in senti-
nel lymph nodes [6,21]. MART-1 and Melan-A are two an-
tibodies to different epitopes of the same antigen and are
complementary to each other. As previously reported,
MART-1 and Melan-A demonstrated predominantly cyto-
plasmic staining of melanoma cells [6]. The monoclonal
antibody (T311) to tyrosinase, has been reported to dem-
onstrate high sensitivity and specificity for melanoma
[13]. It has also demonstrated an immunostaining pattern
in sentinel lymph nodes identical to MART-1 and Melan-
A. We combined these three antibodies as 'MCW melano-
ma cocktail' (Table 1).
In contrast to S-100, these immunomarkers did not ob-
scure nuclear details. In addition, they did not stain the
dendritic cells which are generally prominent in the senti-
nel lymph nodes after the diagnostic biopsy of a primary
lesion. This facilitated unequivocal interpretation of sin-
gly scattered melanoma cells which were otherwise im-
possible to identify in sections immunostained for S-100
due to high noise to signal ratio resulting from numerous
S-100 immunoreactive dendritic cells in the background.
Thus, a highly sensitive immunomarker such as S-100 is
less effective for interpretation of sentinel lymph nodes
for melanoma micrometastases (especially when present
as single cells) than MART-1 and Melan-A [6]. Certain
morphological features help to differentiate melanoma
cells and other non-melanoma cells such as S100 immu-
noreactive dendritic cells in sentinel lymph nodes. How-
ever, as demonstrated in our previous study, it is not
uncommon to face an equivocal situation when S-100
Figure 2
Sentinel lymph node positive for melanoma micrometastases. A- as single cells, B- as groups of cohesive cells, C- Negative con-
trol-sentinel lymph node with metastases of mammary carcinoma (arrow). Note the non-immunoreactivity of mammary carci-
noma and adjacent lymphoid tissue for the cocktail. (A through C- Immunostaining with hematoxylin counterstain).
A B CBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/15
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protein is used as an immunomarker for the interpreta-
tion of single melanoma micrometastases in sentinel
lymph nodes [6]. Based on our previous study with
HMB45 [6] and an initial study with micropthalmia tran-
scription factor [22], these immunomarkers were not
considered suitable for inclusion in the cocktail due to the
immunoreactivity of non-melanoma cells in the sentinel
lymph nodes.
During further evaluation, we confirmed that the single
cells immunostained with HMB45 were mast cells and
not melanophages. Although not reported in the litera-
ture, mast cells in mastocytosis and reactive mast cells in
desmoid tumors also showed immunoreactivity for
HMB45 with granular cytoplasmic immunostaining pat-
tern. The same cells in the immediately adjacent section
were confirmed as mast cell by CD117 (personal experi-
ence). Lack of similar staining in the negative control sec-
tions excludes their non-specific nature. Mast cells are
relatively frequent in sentinel lymph nodes, likely  sec-
ondary to the previous biopsy in the draining field (per-
sonal experience). Occasionaly these cells may present an
interpretation challenge, but they can usually be interpret-
ed as benign [6]. To avoid this interference by HMB45 and
its lower sensitivity in general, HMB45 was not incorpo-
rated in the cocktail.
Out of 188 sections immunostained with the cocktail and
interpreted by all five pathologists collectively, 41 were
positive for melanoma micrometastases (Figure 2A and
2B). Az values amongst the five pathologists interpreting
these sections independently did not show statistically
significant differences, demonstrating excellent
interobserver agreement with the cocktail (Table 2). None
Figure 3
Capsular nevus (arrows). Groups of bland cohesive spindle cells immunoreactive for the cocktail (A and B) in the capsule of the 
sentinel lymph node. *Aadjacent section stained with hematoxylin and eosin (C and D).
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of the 81 sections of mammary carcinoma sentinel lymph
nodes showed immunoreactivity for the cocktail in any of
the non-melanoma cells (Figure 2C) and were interpreted
as negative for melanoma micrometastases by all five
observers.
The cocktail showed favorable detection rate for melano-
ma micrometastases as compared to MART-1 and Melan-
A alone. Of 78 sections, 25 sections were positive for
melanoma micrometastases with the cocktail. However,
only 21 were positive with MART-1 and Melan-A individ-
ually. Thus, MART-1 and Melan-A could not individually
detect melanoma micrometastases in 16% (4/25) of slices
that were positive for melanoma micrometastases with
the cocktail. As expected, combining a monoclonal anti-
body to tyrosinase with MART-1 and Melan-A in the cock-
tail increased the spectrum to encompass three epitopes of
two melanoma antigens (MART-1/Melan-A and tyrosi-
nase). If indicated in the future, additional monoclonal
antibodies showing immunostaining patterns in sentinel
lymph nodes that are similar to these three antibodies
which also posess high specificity for melanoma may be
added to this cocktail, by widening the spectrum for many
melanoma specific antigen epitopes. However, care
should be taken to not include any antibody that may im-
munostain other non-melanoma cells in the sentinel
lymph nodes. Otherwise, such antibodies may contribute
to the deterioration in the specificity of the cocktail com-
promising its application for evaluation of the sentinel
lymph nodes of melanoma.
During the standardization, all 35 melanomas (including
one spindle cell melanoma and one clear cell melanoma)
were immunoreactive with 'the cocktail'. Non-immunore-
activity of special variants of melanoma to various
melanoma immunomarkers is a challenge. During
interpretation of sentinel lymph nodes, the diagnosis of
melanoma is known and the aim is to detect the melano-
ma micrometastases of the known primary. If the sentinel
lymph nodes of special variants of melanoma are negative
by 'the cocktail', it would be prudent to confirm the im-
munoreactivity of the primary lesion for 'the cocktail'. If
the primary melanoma is non-immunoreactive for 'the
cocktail', the negative interpretation of the sentinel lymph
nodes with cocktail in this situation may be confirmed
with other suitable immunomarker to which the primary
melanoma is immunoreactive. The cocktail was not com-
pared with S-100 in this study, as its role in evaluation of
sentinel lymph nodes of melanoma was already demon-
strated to be unreliable even in comparison to MART-1
and Melan-A individually in the previous study [6]. We
did not compare tyrosinase alone with the cocktail be-
cause the questionable contribution of such a study
would not be offset by the additional cost involved. Pub-
lished studies do not report 100% immunostaining with
anti-tyrosinase antibody (T311). Tyrosinase alone or any
other immunomarker used individually, would be less
sensitive than a cocktail. To evaluate the exact impact of
the cocktail in comparison to all of its component immu-
nomarkers individually for evaluation of sentinel lymph
nodes, additional studies dedicated to comparison of in-
dividual component immunomarkers with the cocktail
may be called for.
Capsular nevi in the form of a few cohesive cocktail im-
munoreactive spindle cells with bland elongated nuclei
(Figure 3) were observed in 5% (9/188) of sections (10 %
(9/88) of sentinel lymph nodes and 21% (5/24) of cases.
As compared to this, none of the 81 slices of sentinel
lymph nodes from 30 cases of mammary carcinoma
showed capsular melanocytic nevi. The sentinel lymph
nodes of melanocytic nevi were from different sites and
none were from the axillary region. The exact explanation
for this difference in the prevalence of capsular nevi could
not be deciphered and further evaluation is in process.
The association of higher frequency of capsular melano-
cytic nevi with congenital nevi [23] is one possibility. In
our study, except for the difference in their regional
variation, another possible explanation is the cytokine ef-
fect of the melanoma draining to the sentinel lymph
node. Hypothetically, an association between the higher
prevalence of melanocytic capsular nevi and the predispo-
sition for melanoma may be likely. Although, these
melanocytic capsular nevi appear benign morphological-
ly, a low probability that they may represent subtle metas-
tases was also considered. Further evaluation of these and
other possibilities in larger series is recommended.
Using immunohistochemistry, Yu et al [8] reported capsu-
lar benign melanocytic nevi in 4% (9/235) of sentinel
lymph nodes of melanoma from 9% (8/94) cases (some
cases had more than one sentinel lymph node). Capsular
melanocytic nevi appear to be the most significant benign
lesion that could pose a diagnostic challenge in the inter-
pretation of melanoma micrometastases in sentinel
lymph nodes. For similar reasons, non-in-situ molecular
techniques, such as RT-PCR [6,8,24–29] would have high-
er tendencies for false positive results. Morphology ap-
pears to be the single most important tool facilitating their
correct interpretation [6]. Other approaches, including
the observation that capsular nevi are non-immunoreac-
tive or weakly immunoreactive for HMB45, have been
suggested for differentiating capsular nevi from melano-
ma micrometastases [21]. However, it is important to
note that a significant number of melanomas are also
non-immunoreactive for HMB45. Thus, strong immuno-
reactivity for HMB45 rules out capsular nevus, but non-
immunoreactivity may not be contributory.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/15
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Rather than immunostaining three adjacent sections with
individual antibodies in the cocktail, only one slide is re-
quired which leads to cost savings. Although, the cost of
the three antibodies used in the cocktail has to be in-
curred, the material and labor cost savings for one instead
of three slides is obvious. For proper sampling, some
studies recommend the evaluation of three levels at 200 µ
intervals [30]. In that case, if each of the three antibodies
in the cocktail had to be used individually, it would re-
quire the immunostaining, interpreting, and correlating
of nine sections. In contrast to this, the cocktail requires
only three sections, each at intervals of 200 µ. Thus, use of
the cocktail in concert with any protocol with reference to
number of sections to be evaluated and proportion of sen-
tinel lymph node to be sampled [30,31] would achieve
obvious cost saving.
The most ideal positive control would be the sausage of
three controls immunoreactive individually for one of the
antibodies but non-immunoreactive for other two respec-
tive antibodies in the cocktail. However, this is a difficult
positive control to get. The positive control used by us
showed subtle differences when immunostained with
each individual antibody in the cocktail with some areas
slightly darker than others. However, when the same con-
trol was immunostained with the cocktail, the entire con-
trol showed relatively homogeneous immunostaining.
The change in this immunostaining pattern would suggest
the deterioration of one of the component which can be
correlated with the same control immunostained with the
individual antibodies. In addition, another precaution
taken by us was that the cocktail was prepared after peri-
odically evaluating individual antibodies with the posi-
tive control. This later approach is the best alternative.
Conclusions
It is possible to use a combination of monoclonal anti-
bodies to MART-1, Melan-A, and Tyrosinase as a single
cocktail reagent on one glass slide in contrast to three in-
dividual antibodies on three slides. The cocktail facilitated
easy detection and interpretation of melanoma microme-
tastases in sentinel lymph nodes with reproducible inter-
observer results. There was favorable increase in the detec-
tion rate of melanoma micrometastases in sentinel lymph
nodes as compared to MART-1 and Melan-A individually.
Furthermore, this approach leads to obvious cost savings
and simplifies the interpretation by reducing the number
of slides to be evaluated.
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